Despite the tolerance of some DMD patients to micro-dystrophin therapy [49,75], the spatiotemporal expression of micro-dystrophin is actually modulated by an exogenous promoter within the AAV, which may lead to uncontrollable protein localization and level. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.